|
Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi
(Preview)
http://hepatitiscnewdrugs.blogspot.com/2014/12/class-action-lawsuit-challenges.html
|
Matt Chris
|
10
|
2190
|
|
|
|
|
The cost
(Preview)
http://www.huffingtonpost.com/jeffrey-sachs/the-drug-that-is-bankrupt_b_6692340.html?utm_hp_ref=business&ir=Business
|
Stormy
|
1
|
1345
|
|
|
|
|
New Drugs, Shorter Treatment ????
(Preview)
Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?By Todd Campbell | More Articles February 16, 2015 | Tiny biotech stock Achillion Pharmaceuticals (NASDAQ: ACHN ) reported what could be pretty big news for hepatitis C patients this week. The clinica...
|
suziq
|
9
|
1572
|
|
|
|
|
Gilead's discount for Germany
(Preview)
Now we're talking! Gilead will supply Germany at almost half price. I hope Australia can get a similar bargain. I guess Gilead had to start high but we're starting to see the benefits of competition. http://www.reuters.com/article/2015/02/12/us-gilead-sciences-hepatitis-germany-idUSKB...
|
mallani
|
3
|
1051
|
|
|
|
|
February issue of HCV Advocate Newsletter
(Preview)
Hi all, Here's the February issue of the Newsletter. Some points: After I'd failed Interferon 3 times, I was told 'Geno 1b is the hardest to treat'. Times have changed. Also. it's interesting that 70% of cirrhotics may have no symptoms- I certainly didn't. Cheers. http://www.hcvadvocate.org/new...
|
mallani
|
0
|
841
|
|
|
|
|
Sales of Gilead`s Sovaldi Soar to $10.3 Billion
(Preview)
[url]http://www.nytimes.com/2015/02/04/business/sales-of-s...
|
Cinnamon Girl
|
2
|
1443
|
|
|
|
|
HCV Advocate Blog
(Preview)
Hi all, For new members wanting to keep up to date, this Blog is one of the best. It's very rare for them to miss something. We usually give a link to the HCV Advocate Newsletter each month, but this is good as well. Cheers. http://hcvadvocate.blogspot.com.au/
|
mallani
|
0
|
753
|
|
|
|
|
Gilead criticised by MSF on expanded voluntary licence agreement of GS-5816 in India
(Preview)
The well-known international humanitarian organisation Médecins Sans Frontières has strongly criticised the decision by US-based Gilead Sciences to expand its existing voluntary licence agreement with eight Indian generic drug-makers for sofosbuvir and ledipasvir to include its investi...
|
Cinnamon Girl
|
1
|
962
|
|
|
|
|
Liver damage and repair
(Preview)
Hello, One week of Harvoni behind me and all is well! I'm very happy to say that. I have heard that the liver does an excellent job of healing it's self. Does anybody know if the fibrosis will heal and go away after the body has cleared the virus?....Roger
|
rblood
|
13
|
1999
|
|
|
|
|
News from Australia
(Preview)
Looks like wonderful news from Australia--if it can be implemented. Interesting article. Key role for Hep C Inquiry- By 2030 there should be no deaths in Australia related to hepatitis C SuziQ
|
suziq
|
1
|
796
|
|
|
|
|
Study on Cognitive Dysfunction and Fatigue
(Preview)
From the American Academy of Neurology: Recently published data from a study on imaging abnormalities, neurocognitive function and fatigue in patients with HCV. "It has long been known that HCV is hepatotoxic; increasingly there is reason to believe that it is neurotoxic as well. While t...
|
OldenSlow
|
2
|
952
|
|
|
|
|
Merck Voluntarily Discontinuing VICTRELIS in the U.S.
(Preview)
Here`s an extract from Merck`s recent letter to pharmacy professionals concerning the voluntary discontinuation of Victrelis by Dec 2015."SUBJECT: Merck Voluntarily Discontinuing VICTRELIS (boceprevir) 200 mg CapsulesDear Pharmacy Professional: We would like to inform you that Merck has...
|
Cinnamon Girl
|
5
|
1001
|
|
|
|
|
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX + EXVIERA
(Preview)
NORTH CHICAGO, Ill., Jan. 16, 2015 -- AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets).The treatment h...
|
Cinnamon Girl
|
0
|
922
|
|
|
|
|
NICE (UK) plans to support new device for diagnosing liver damage without surgery
(Preview)
NICE is consulting on draft guidance on a device that aims to diagnose and monitor liver damage, without the need for surgery. The provisional recommendations support using the device, Virtual Touch Quantification (VTq), in adults and children with chronic hepatitis B or C who need assessment o...
|
Cinnamon Girl
|
0
|
718
|
|
|
|
|
Sofosbuvir delayed by NHS England due to high cost
(Preview)
The NHS (National Health Serive) in England has taken the decision to delay the use of sofosbuvir because of the hight cost. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofos...
|
Cinnamon Girl
|
2
|
1414
|
|
|
|
|
Prime Therapeutics Formulary News
(Preview)
"There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first," said Peter Wickersham, senior vice president of Integrated Care and Specialty, Prime. "It was clear that neither Gilead nor AbbVie wanted...
|
OldenSlow
|
2
|
1095
|
|
|
|
|
March meeting for Australians
(Preview)
Hi all, The March meeting of the PBAC here, will be the busiest for some time. This will decide whether some DAA HepC treatments are made available to Australians. The drugs are: Sunvepra (Asunaprevir) Daklinza (Daclatasvir) Harvoni (Sovaldi/Ledipasvir) Sovaldi A brief look at the Australian Fo...
|
mallani
|
1
|
983
|
|
|
|
|
Something NEW in HCV News
(Preview)
Benitec Advances Hepatitis C Clinical TrialSYDNEY, Jan. 7, 2015 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) is pleased to advise that the third patient in its Phase I/IIa clinical trial of TT-034 for hepatitis C was dosed earlier today at the Duke Clinical Research Unit (USA)...
|
Brownie
|
4
|
1278
|
|
|
|
|
Gilead makes deal with CVS
(Preview)
Well, looks like Sovaldi and Harvoni will get exclusive coverage on several plans from CVS/Caremark. http://www.cnbc.com/id/102310444#.
|
maddie
|
2
|
1060
|
|
|
|
|
Upcoming Webinar on Viekira Pak - Clinical Care Options
(Preview)
Registration required, but it is straightforward and free. Questions can be submitted during registration process: https://www.regonline.com/register/checkin.aspx?EventId=1661952&MethodId=0&EventSessionId=&startnewreg=1 ----------------------...
|
OldenSlow
|
4
|
1180
|
|
|
|
|
HCV Advocate Newsletter- January 2015
(Preview)
Hi all, Herewith the January 2015 edition of the HCV Advocate Newsletter. http://www.hcvadvocate.org/news/newsLetter/2015/advocate0115.html
|
mallani
|
3
|
893
|
|
|
|
|
RG-101 In Early Trials
(Preview)
http://www.fool.com/investing/general/2015/01/02/how-1-tiny-hepatitis-c-drug-developer-trounced-gil.aspx
|
inthewind
|
1
|
788
|
|
|
|
|
Express Scripts Drops Harvoni 12/2014
(Preview)
http://www.reuters.com/article/2014/12/22/express-scripts-abbvie-hepatitisc-idUSL1N0U50M120141222  Dec 22 (Reuters) - The nation's largest pharmacy benefit manager has lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C treatment and, in most cases...
|
pamelajean
|
6
|
3808
|
|
|
|
|
New Updated AASLD Guidelines includes Harvoni and new AbbVie drugs
(Preview)
These are the new AASLD guidelines posted: Compensated Cirrhosis Genotype 1A Three options with similar efficacy in general are recommended for treatment-naive patients with HCV genotype 1a infection (listed in alphabetic order; see text).Daily fixed-dose combination of ledipasvir (90 mg)...
|
Beacon
|
3
|
1610
|
|
|
|
|
AbbVie gets FDA approval
(Preview)
Hi all, As expected, the AbbVie combo obtained FDA approval. The price has not been announced as yet. Good luck to them-they'll need it to get a slice of the HCV treatment pie. Cheers. http://www.nytimes.com/2014/12/20/business/abbvie-wins-approval-of-hepatitis-c-treatment.html?_r=0 ...
|
mallani
|
7
|
1127
|
|
|
|
|
New AbbVie drug approval and price
(Preview)
Abbvie's Viekira Pak Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan. Some insurers and analysts had said that AbbVie might price its drug, which will be sold under t...
|
Beacon
|
0
|
722
|
|
|
|
|
HCV Drugs - Quick Reference
(Preview)
I found a small guide that lists approved HCV drugs and those currently in development. It offers some background info, dates and rates of success which are figures from the author, so additional confirmation of those numbers may be required. But the simplicity of the info made it interesting and wo...
|
Tig
|
0
|
991
|
|
|
|
|
Dec.2014 - HCV Advocate Newsletter
(Preview)
[url]http://www.hcvadvocate.org/news/newsLetter/2014/advocate1214.html#2[...
|
Cinnamon Girl
|
3
|
1109
|
|
|
|
|
Snapshots from AASLD 2014
(Preview)
Snapshots from AASLD 2014, by Lucinda K. Porter, RNLots of interesting reading here, for anyone interested. "December`s Snapshots typically features abstracts presented at the recent Liver Meeting. The research presented here was gathered from conference posters, presentations and abstr...
|
Cinnamon Girl
|
1
|
699
|
|
|
|
|
sumthing about Gillead on mainstream news website......
(Preview)
http://www.msn.com/en-us/money/insurance/costly-hepatitis-%E2%80%98c%E2%80%99-drug-makers-face-new-fire/ar-BBgkEi9
|
Josh Haynie
|
4
|
1003
|
|
|
